NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets
NorthStrive Biosciences, a subsidiary of PMGC Holdings (ELAB), filed two new U.S. patent applications covering the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss. The filings expand the company's intellectual property portfolio from animal health into potential human-use applications, targeting muscle loss from sarcopenia, malnutrition, and physical inactivity.
Key figures
- Patent applications
- ["19/709,895","19/709,950"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.